Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 0.4% – What’s Next?

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) rose 0.4% during mid-day trading on Monday . The company traded as high as $5.95 and last traded at $5.72. Approximately 17,352 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 47,896 shares. The stock had previously closed at $5.70.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $32.00.

Cadrenal Therapeutics Trading Up 0.4%

The firm’s 50-day moving average price is $7.90 and its two-hundred day moving average price is $10.87. The stock has a market cap of $13.38 million, a PE ratio of -0.71 and a beta of 1.18.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.55) by $0.24. On average, analysts anticipate that Cadrenal Therapeutics, Inc. will post -7.59 earnings per share for the current year.

Insider Transactions at Cadrenal Therapeutics

In other news, CFO Matthew K. Szot sold 9,933 shares of Cadrenal Therapeutics stock in a transaction on Monday, December 29th. The stock was sold at an average price of $6.97, for a total value of $69,233.01. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 26.09% of the company’s stock.

Institutional Investors Weigh In On Cadrenal Therapeutics

Hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in Cadrenal Therapeutics during the third quarter valued at about $274,000. Geode Capital Management LLC lifted its position in shares of Cadrenal Therapeutics by 14.3% during the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Cadrenal Therapeutics during the third quarter valued at about $103,000. 7.92% of the stock is currently owned by hedge funds and other institutional investors.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.